Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Study Supports Pfizer, Moderna COVID-19 Vaccines’ Safety in Patients With Multiple Myeloma

January 26th 2022, 10:15pm


Study results showed that both the Pfizer-BioNTech and Moderna COVID-19 vaccines were safe and effective in patients with multiple myeloma, which investigators hope will improve vaccine hesitancy in the high-risk population.

Screening Initiative Identifies Those at Highest Risk of Developing MM

January 19th 2022, 5:00pm


Research presented at the 2021 American Society of Hematology Annual Meeting and Exposition highlights efforts in screening for multiple myeloma (MM).

Updated GRIFFIN Data Show Safety, Efficacy of Adding Daratumumab in NDMM Maintenance

January 17th 2022, 5:30pm


Can daratumumab be taken safely as a maintenance therapy? Will quadruplet therapy become more common in the treatment of newly diagnosed multiple myeloma (NDMM)?

Novel Therapy for Multiple Myeloma: Future Directions in Care

January 14th 2022, 3:40pm


Looking toward the future management of patients with multiple myeloma, Rafael Fonseca, MD, shares excitement for novel therapeutic strategies.

2-Year Followup Data From the GRIFFIN Trial in Transplant-Ineligible NDMM

January 14th 2022, 3:20pm


Updated results from the GRIFFIN trial in newly diagnosed multiple myeloma, including consideration for frontline 4-drug regimens and depth of response.

Multiple Myeloma: Current Approaches to Frontline Therapy

January 14th 2022, 3:00pm


Taking into account data from the ASH 2021 annual meeting, Rafael Fonseca, MD, reviews his current approaches to frontline therapy for patients with multiple myeloma.

Rescue Isatuximab in Transplant-Ineligible, Treatment Naïve NDMM

January 14th 2022, 2:40pm


Rafael Fonseca, MD, reviews data on rescue isatuximab from the ASH 2021 annual meeting and discusses use of best therapies up front.

Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM

January 14th 2022, 2:20pm


Insight on the survival benefit seen with frontline daratumumab-based regimens in patients with transplant-ineligible multiple myeloma.

The MASTER Trial: Frontline Dara-KRd in Newly Diagnosed Multiple Myeloma

January 14th 2022, 2:00pm


Expert perspective on results from the MASTER trial, which analyzed dara-KRd as frontline therapy with MRD-adapted use in newly diagnosed multiple myeloma.

Dr Robert Rifkin on Future Investigations Into Multiple Myeloma

January 13th 2022, 4:30pm


Robert Rifkin, MD, FACP, a medical oncologist and hematologist at Rocky Mountain Cancer Centers, outlines multiple myeloma research he hopes to see in the next 5 years.